Tarsus board member Rosemary Crane resigns, becomes consultant; committee changes

Tarsus Pharmaceuticals, Inc.

Rosemary Crane resigned from Board and committees effective Jan 17, 2025; not due to any disagreement.
Crane entered a 6-month consulting agreement with Tarsus, continuing to vest in equity awards.
Wendy Yarno appointed Chairperson of Commercial Committee; steps off Audit Committee effective Jan 17.
Andrew Goldberg, M.D. appointed to Audit Committee effective Jan 17, 2025.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rosemary Crane

Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2025-01-17
Filed: January 17, 2025, 6:59 PM ET

On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rosemary Crane resigned as Director at Tarsus Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-25-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.